Cherng, H. J., Alig, S. K., Oki, Y., Nastoupil, L. J., Fayad, L., Neelapu, S. S., . . . Westin, J. R. (2023). A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Advances, 7(7), 1137-1145. https://doi.org/10.1182/bloodadvances.2022008174
Chicago Style (17th ed.) CitationCherng, Hua-Jay J., et al. "A Phase 1/2 Study of Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed DLBCL." Blood Advances 7, no. 7 (2023): 1137-1145. https://doi.org/10.1182/bloodadvances.2022008174.
MLA (8th ed.) CitationCherng, Hua-Jay J., et al. "A Phase 1/2 Study of Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed DLBCL." Blood Advances, vol. 7, no. 7, 2023, pp. 1137-1145, https://doi.org/10.1182/bloodadvances.2022008174.
Warning: These citations may not always be 100% accurate.
Visit our Citation Styles guide for help on properly citing sources.
Visit our Citation Styles guide for help on properly citing sources.